Group 1 - The company plans to focus on innovative drug research and development, including advancing the Phase III clinical trial of the modified new drug Palivizumab inhalation solution and initiating the Phase I clinical trial of oral lyophilized powder of Diphenylhydantoin [1] - The company reported a significant decline in revenue, achieving 61.8463 million yuan, a year-on-year decrease of 71.28%, and a net loss attributable to shareholders of 40.0023 million yuan [1] - The decline in performance is attributed to industry policy environment, intensified market competition, and reduced sales of high-margin products due to lower flu cases and insufficient market demand [1] Group 2 - The company announced plans to acquire a group of assets from Future Pharmaceuticals for no more than 480 million yuan, which includes both marketed and in-development products related to multi-trace element injection [2] - As of June 30, 2025, the company's cash balance was 439 million yuan, and the acquisition has raised concerns about depleting financial resources [3] - The company believes that the acquisition aligns with its "big health" development strategy and will enhance its product pipeline, optimizing its product layout in "anti-infection - chronic disease - nutritional support" [3]